diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 2220e30b..377f3150 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -71,6 +71,12 @@ The sarcopenic obesity mechanism creates a pathway where GLP-1s may INCREASE hea WHO issued conditional recommendations (not full endorsements) for GLP-1s in obesity treatment, explicitly acknowledging 'limited long-term evidence.' The conditional framing signals institutional uncertainty about durability of outcomes and cost-effectiveness at population scale. WHO requires countries to 'consider local cost-effectiveness, budget impact, and ethical implications' before adoption, suggesting the chronic use economics remain unproven for resource-constrained health systems. + +### Additional Evidence (challenge) +*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16* + +Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF the typical semaglutide dose when paired with digital behavioral support, matching clinical trial results at 50% drug cost. If this half-dose protocol proves generalizable, it could fundamentally alter the inflationary cost trajectory by reducing per-patient drug spending while maintaining efficacy. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 3d9ef0bb..518add3b 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -59,6 +59,12 @@ The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2 The discontinuation problem is worse than just lost metabolic benefits - it creates a body composition trap. Patients who discontinue lose 15-40% of weight as lean mass during treatment, then regain weight preferentially as fat without muscle recovery. This means the most common outcome (discontinuation) leaves patients with WORSE body composition than baseline: same or higher fat, less muscle, higher disability risk. Weight cycling on GLP-1s is not neutral - it's actively harmful. + +### Additional Evidence (extend) +*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16* + +Digital behavioral support may partially solve the persistence problem: UK study showed 11.53% weight loss with engagement vs 8% without at 5 months, suggesting the adherence paradox has a behavioral solution component. However, high withdrawal rates in non-engaged groups suggest this requires active participation, not passive app access. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.json b/inbox/archive/.extraction-debug/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.json new file mode 100644 index 00000000..a7b5bf86 --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.json @@ -0,0 +1,26 @@ +{ + "rejected_claims": [ + { + "filename": "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 3, + "rejected": 1, + "fixes_applied": [ + "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md:set_created:2026-03-16", + "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d", + "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md:stripped_wiki_link:GLP-1 receptor agonists are the largest therapeutic category" + ], + "rejections": [ + "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.md b/inbox/archive/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.md index 9ff56b5e..348224d6 100644 --- a/inbox/archive/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.md +++ b/inbox/archive/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.md @@ -7,9 +7,13 @@ date: 2025-01-01 domain: health secondary_domains: [] format: study -status: unprocessed +status: enrichment priority: high tags: [glp-1, adherence, digital-health, weight-loss, tirzepatide, behavioral-support, obesity] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -60,3 +64,12 @@ A retrospective cohort service evaluation study published in the Journal of Medi PRIMARY CONNECTION: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox (March 12 claim candidate) WHY ARCHIVED: Convergent evidence that digital behavioral support partially solves the GLP-1 adherence problem — changes the economic model under capitation if sustained EXTRACTION HINT: Focus on the half-dose finding (cost efficiency) and the convergence with WHO guidelines (behavioral combination is now international standard). Scope carefully — observational, not RCT. + + +## Key Facts +- Voy platform components include live group video coaching, text-based support, educational content, weight monitoring, and adherence tracking +- UK Voy study showed high withdrawal rate in non-engaged group limiting generalizability +- Tirzepatide users outperformed semaglutide users: 13.9% vs 9.5% at 5 months in Voy cohort +- WHO December 2025 guidelines recommend combining GLP-1 with intensive behavioral therapy +- Danish study was 64 weeks duration, UK Voy study was 5 months +- All three studies (UK, Danish, Wiley) were retrospective/observational, not RCTs